Tempus AI
Nasdaq TEM · Chicago, IL
Works in Cardiovascular · Dermatology · ENT · GI & liver · Hematology · Immunology · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health
Tempus AI is a clinical trial sponsor based in Chicago, IL, listed as Nasdaq TEM. It has 10 active clinical trials with 7,050 planned participants, across 13 therapeutic areas. Since 2021 it has completed 2 trials and stopped 1 early. Its FDA record on file shows 1 inspection.
Trial track record · since 2021
FDA record
Recent FDA actions
Financials · Nasdaq TEM
Pipeline · 10 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Tempus AI
No warning letter naming Tempus AI is on file. FDA has published 1 inspection classification naming it.
FDA has posted 1 inspection classification naming Tempus AI. The latest inspection ended on 2026-04-21 and was classified NAI (no action indicated). FDA posts a classification after its review, often months after the inspection ended.
Tempus AI is lead sponsor of 10 active clinical trials on ClinicalTrials.gov, with 7,050 planned participants, in Cardiovascular, Dermatology, ENT, GI & liver and other areas. Since 2021 it has completed 2 trials and stopped 1 early.
Tempus AI is based in Chicago, IL and is listed as Nasdaq TEM. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Tempus AI; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-09.
The FDA record counts inspection classifications, warning letters and recalls FDA has published that name this company. Compare it with the industry in the free CDMO FDA inspection lookup.
Approve Suite is not affiliated with Tempus AI.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.